Immunomedics

2 Biotechs With Approaching Drug Approvals
2 Biotechs With Approaching Drug Approvals
Motley Fool
drug approvals
drug launches
FDA
voxelotor
Global Blood Therapeutics
Immunomedics
sacituzumab govitecan
Flag link:
The Week Ahead In Biotech: Spotlight On ESMO Conference
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Flag link:
These 6 biotech stocks are promising takeover targets
These 6 biotech stocks are promising takeover targets
Marketwatch
M&A
Sarepta Therapeutics
Amarin
Intercept Pharmaceuticals
Immunomedics
Alder Biopharmaceuticals
Biogen
Flag link:
With Immunomedics ADC deal, Everest bolsters cancer pipeline
With Immunomedics ADC deal, Everest bolsters cancer pipeline
BioCentury
Immunomedics
sacituzumab govitecan
Everest Medicines
Asia
Flag link:
Immunomedics CEO Michael Pehl hits the exit on the heels of a CRL and accusations of a data integrity breach
Immunomedics CEO Michael Pehl hits the exit on the heels of a CRL and accusations of a data integrity breach
Endpoints
Immunomedics
Michael Pehl
Flag link:
FDA uncovers data manipulation at Immunomedics plant making cancer drug
FDA uncovers data manipulation at Immunomedics plant making cancer drug
Fierce Pharma
FDS
Immunomedics
sacituzumab govitecan
drug manufacturing
Flag link:
Immunomedics, still searching for first approval, discloses forthcoming FDA re-inspection
Immunomedics, still searching for first approval, discloses forthcoming FDA re-inspection
Biopharma Dive
Immunomedics
FDA
sacituzumab govitecan
Flag link:
FDA rejects Immunomedics breast cancer drug, extending long regulatory drought
FDA rejects Immunomedics breast cancer drug, extending long regulatory drought
Stat
Immunomedics
FDA
breast cancer
sacituzumab govitecan
Flag link:
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
CP Wire
Immunomedics
FDA
sacituzumab govitecan
triple negative breast cancer
Flag link:
Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today
Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today
Motley Fool
Immunomedics
ASCO 2018
sacituzumab govitecan
breast cancer
Flag link:
After months of searching, Immunomedics lines up Celgene vet Pehl as its new CEO
After months of searching, Immunomedics lines up Celgene vet Pehl as its new CEO
Fierce Biotech
Immunomedics
Celgene
Pharma CEOs
Michael Pehl
Flag link:
Will Seattle Genetics' Deal With Immunomedics Get Scuttled?
Will Seattle Genetics' Deal With Immunomedics Get Scuttled?
Motley Fool
Seattle Genetics
Immunomedics
IMMU-132
Flag link:
Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News
Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News
TheStreet.com
Immunomedics
Seattle Genetics
M&A
solid tumors
Adcetris
Flag link:
7 Biopharma Companies That Destroyed Shareholders Last Week
7 Biopharma Companies That Destroyed Shareholders Last Week
24/7 Wall St
ProNai
Adamis Pharmaceuticals
Ocular Therapeutics
Mirati Therapeutics
Immunomedics
Valeant Pharmacueticals
Biogen
Flag link:
Immunomedics' ASCO Letdown
Immunomedics' ASCO Letdown
Motley Fool
ASCO 2016
Immunomedics
Flag link:
Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure
Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure
Motley Fool
biotech
ASCO 2016
Biogen
Immunomedics
AbbVie
Juno Therapeutics
Kite Pharma
Flag link:
Immunomedics Kicked Out of Prestigious ASCO Cancer Conference
Immunomedics Kicked Out of Prestigious ASCO Cancer Conference
TheStreet.com
Immunomedics
triple negative breast cancer
ASCO 2016
IMMU-132
Flag link:
10 Worst NASDAQ Biotech Stocks in the Third Quarter
10 Worst NASDAQ Biotech Stocks in the Third Quarter
TheStreet.com
Orexigen
Immunomedics
Celldex Therapeutics
Arena Pharmaceuticals
Theravance
Karyopharm
Raptor Pharmaceutical
Verastem
Tetraphase
Xoma
Flag link:
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer
24/7 Wall St
biotech
ASCO
Immunogen
Exelixis
Oncothyreon
CTI BioPharma
Immunomedics
Vascular Biogenics
Flag link:
16 Biotech Stocks Moving Off The ASCO Conference
16 Biotech Stocks Moving Off The ASCO Conference
Yahoo/Benzinga
biotech
ASCO
Bristol-Myers Squibb
Immunogen
Oncothyreon
Clovis Oncology
CTI BioPharma
Exelixis
Roche
Amgen
AstraZeneca
Puma Biotechnology
Vascular Biogenics
Immunomedics
Momenta
Eli Lilly
Juno Therapeutics
Express Scripts
Flag link:

Pages